|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Whether you are a healthcare professional, a patient or simply someone looking to know more about the complete solutions offered by Cordis, let us show you how our distinctive approach to working in partnership with you results in innovative interventional products and services to help support sustained patient outcomes.
House Votes to Repeal IPAB
This week, the U.S. House of Representatives voted to pass H.R. 1190, the Protecting Seniors' Access to Medicare Act, the bill that would repeal the Independent Payment Advisory Board (IPAB). SCAI and its partner societies in the Alliance of Specialty Medicine have urged repeal of this Affordable Care Act-mandated government board whose sole purpose is to reduce Medicare spending. SCAI opposed formation of the IPAB and advocated for its repeal because of its potential to severely restrict Medicare beneficiaries' access to care.
The House voted 244 to 154 to pass H.R. 1190. The next step for this legislation is the Senate, where it may meet stronger opposition. Stay tuned for information about how you can help SCAI support the bill.
Learn more about IPAB.
Image of the Week: How to Use OCT to Guide Antegrade Dissection/
Re-entry During CTO
Emmanouil Brilakis, MD, PhD, FSCAI, of Dallas VA Medical Center and UT Southwestern Medical Center, presents a case illustrating the use of OCT to guide antegrade dissection and re-entry during right coronary CTO PCI. This case demonstrates how OCT can provide valuable insight into making a correct diagnosis. What is the correct diagnosis?
The SCAI Imaging Center is developed and maintained with the generous support of St. Jude Medical. SCAI gratefully acknowledges this support while taking sole responsibility for all content developed and disseminated through this effort.
GLIDESHEATH SLENDER® 5Fr and 7Fr!
The only family of unique thin-wall sheaths, offering radial access to more patients.
• Increase Your Radial Access Options
• Optimize Procedural Outcomes
• Preserve Arterial Function
*GLIDESHEATH SLENDER® is currently available in 6Fr.
©2015 Terumo Medical Corporation. All rights reserved.
All brand names are trademarks or registered trademarks of Terumo. TIS-694-06012015
New President's Page: How SCAI Is Enhancing Patient Care Through Quality
For his latest President's Page, James Blankenship, MD, MHCM, FSCAI, teamed up with Quality Improvement Committee Chair Sunil Rao, MD, FSCAI, to examine SCAI's ongoing work to improve patient care by focusing on quality. While SCAI's commitment to quality dates back to the goals of the Society's founders, the last five years have seen significant committee expansion and new emphasis on providing practical, hands-on tools for the entire cath lab team.
Click here to read the newly e-published President's Page in Catheterization & Cardiovascular Interventions.
Have You Downloaded the SCAI PCI Risk Calculator App?
SCAI's PCI Risk Calculator App allows healthcare providers to enter preprocedural patient information into one calculator to estimate the post-intervention risks for mortality, acute kidney injury and transfusion.
This tool can also be used to:
Access the app now:
- Guide patients in decisions on therapy
- Guide providers in preparing the patient for the procedure
- Help providers use limited healthcare resources more wisely
- Guide quality improvement efforts
- Serve as a risk adjustment tool for assessment of quality of care to identify potential candidates for same-day discharge or risk mitigation strategies
Access the Web application
The SCAI PCI Risk Calculator was developed with the generous support of The Medicines Company. SCAI gratefully acknowledges this support while taking sole responsibility for all content developed and disseminated through this effort.
SCAI Offering 50 Percent Off Membership to Graduating Fellows-in-Training
SCAI expresses its congratulations to all interventionalists-in-training who have completed or will be completing their interventional cardiology fellowship training program!
The Society recognizes this is an exciting time in your career, a time when opportunities may be plentiful but resources limited. It may also be the point in your career when you most need to be part of a community, a member of an organization whose members share your values and your goals.
With that said, SCAI is offering 50 percent off first year's dues for all new interventionalists!
Click here for details on this offer and to learn how it can help you launch your career.
Building a Better Valve
The New York Times
TAVR is part of the changing face of cardiac care in the United States. But even as speedier treatment has helped slash the death toll from heart attacks over all in the past decade, the number of deaths from heart failure caused by aortic valve disease has risen 35 percent, in large part because more people are living long enough to develop it. More than 8,000 Americans die from the disease annually. It is an illness of aging, and an estimated 100,000 Americans are too old or sick for surgery and with a seriously narrowed valve. But recent studies in very sick patients have found the new procedure prolonged lives, offering new hope that the death toll from narrowing valves can be reduced.
A Sea Change in Treating Heart Attacks
The New York Times
The death rate from coronary heart disease has dropped 38 percent in a decade. One reason is that hospitals rich and poor have streamlined emergency treatment, slashing the time it takes to clear a blockage in a patient's arteries and get blood flowing again to the heart. Hospitals across the country have adopted common-sense steps that include having paramedics transmit electrocardiogram readings directly from ambulances to emergency rooms and summoning medical teams with a single call that sets off all beepers at once.
FDA Approves Cangrelor for Reducing Thrombotic Events in PCI Setting
Cangrelor, an intravenous antiplatelet agent, is now approved by the Food and Drug Administration for reducing thrombotic events in patients undergoing percutaneous coronary intervention. The FDA approval is based on data from the large-scale CHAMPION-PHOENIX study, an 11,145-patient randomized trial comparing intravenous cangrelor against clopidogrel.
FDA Approves Third-generation Sapien Transcatheter Heart Valve
The Food and Drug Administration has approved the third-generation Sapien transcatheter heart valve for the treatment of patients with aortic stenosis.
The Sapien 3, which is approved for patients who are unable to undergo aortic-valve-replacement surgery or are considered high risk for surgery, includes a design change over previous iterations in that it features a polyethylene terephthalate outer skirt designed to minimize paravalvular leak.
FDA Approves Recapturable Transcatheter Aortic Heart Valve
Medtronic announced that it has received Food and Drug Administration approval for a new recapturable, self-expanding system for transcatheter aortic valve replacement for treatment of patients with severe aortic stenosis who are at high or extreme risk for surgery. The CoreValve Evolut R System device is the first recapturable, self-expanding, transcatheter heart valve approved in the United States, according to a company press release.
NOACs Gain Favor for Hospitalized Patients
Reuters via MedPage Today
Novel oral anticoagulants are gaining on warfarin for preventing stroke or transient ischemic attack in hospitalized patients with atrial fibrillation, according to new research. In a paper online June 9 in Circulation: Cardiovascular Quality and Outcomes, Dr. Priyesh A. Patel, of Duke Clinical Research Institute and colleagues noted that novel oral anticoagulants reduce the need for routine monitoring, have a more predictable anticoagulant effect and improved cost-effectiveness in populations at high risk for stroke.
Meta-analysis: LAA Closure Confers CV Mortality Benefit Versus Warfarin in AF
Findings from a meta-analysis of the PROTECT AF and PREVAIL trials indicated that left atrial appendage closure yielded a survival benefit compared with warfarin in patients with nonvalvular atrial fibrillation. The researchers assessed data from the PROTECT AF and PREVAIL randomized controlled trials to compare left atrial appendage closure versus warfarin for the prevention of stroke, systemic embolism and cardiovascular death.
Catheter-delivered Gene Therapy Yields Positive Signal in Advanced Heart Failure
Endomyocardial injection of DNA encoding stromal cell-derived factor 1 in patients with chronic ischemic heart failure tends to attenuate cardiac remodeling, according to a phase II study published online June 8 ahead of print in the European Heart Journal. While the gene therapy failed to meet its primary efficacy endpoint, significant functional improvement was seen in those with the lowest levels of left ventricular ejection fraction.
Cath Lab Teams: A Look at Cath Lab Pay and How You Might Do Better
If you work in a cath lab, take a look at the information in SpringBoard Healthcare's 2015 survey. Its results shed light on wage information from directors and managers to nurses and technologists.
For a complete list of job postings, click here
To post your resume, click here
||SCAI Fellows Course at LWSIC
||SCAI TAVR Session @ SOLACI
||Mexico City, MEXICO
||SCAI China Fellows Course
||SCAI CPVI - Complex Peripheral Vascular Interventions
SCAI at Great Wall International Congress of Cardiology
SCAI Fellows Course at AICT 2015
||SCAI 2015 Fall Fellows Courses
||SCAI Session at CardioEgypt 2016
|May 4-7, 2016
||SCAI 2016 Scientific Sessions
CLICK HERE for a Full Calendar of SCAI Events
The news summaries appearing in SCAI This Week are based on original information from news organizations and are produced by Multibriefs, an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI This Week constitute the official opinion of SCAI.
The SCAI This Week news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI This Week may be directed to Multibriefs at firstname.lastname@example.org.
Missed last week's issue? See which articles your colleagues read most.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063